Aethlon Medical(AEMD) - 2026 Q2 - Quarterly Results

Financial Performance - Aethlon Medical reported a cash balance of approximately $5.8 million as of September 30, 2025[16]. - Consolidated operating expenses for the fiscal second quarter decreased by approximately $1.4 million or 48%, from $2.9 million in the same period in 2024 to approximately $1.5 million[17]. - The operating loss for the quarter decreased to $1.5 million compared to $2.8 million in the prior-year period[18]. - Net loss for the three months ended September 30, 2025, was $1,487,100 compared to a net loss of $2,806,973 for the same period in 2024, indicating a 47% improvement[33]. - Total operating expenses for the six months ended September 30, 2025, were $3,302,220, down from $5,521,856 in the prior year, a decrease of approximately 40%[33]. - Basic and diluted loss per share for the three months ended September 30, 2025, was $3.74, significantly lower than $16.11 for the same period in 2024[33]. - Professional fees for the three months ended September 30, 2025, were $393,796, down from $570,845 in the same period last year, a decrease of about 30.9%[33]. - Payroll and related expenses decreased to $594,611 from $1,372,899 year-over-year, a reduction of approximately 56.7%[33]. - Other comprehensive loss for the three months ended September 30, 2025, was $(4,000) compared to a gain of $3,804 in the same period last year[33]. Assets and Liabilities - Total current assets increased to $6,253,879 from $5,949,800, representing a growth of approximately 5.1%[31]. - Total liabilities decreased to $1,577,113 from $2,236,004, a reduction of about 29.5%[31]. - Total stockholders' equity rose to $5,745,977 from $5,123,530, an increase of approximately 12.2%[31]. - Cash and cash equivalents increased to $5,853,493 from $5,501,261, reflecting a growth of about 6.4%[31]. Research and Development - Recruitment for the second cohort of the Australian oncology trial of the Hemopurifier® is underway, evaluating safety and feasibility in patients with solid tumors[5]. - The study's primary endpoint is safety, enrolling approximately 9 to 18 participants with escalating doses of Hemopurifier treatment[12]. - Improvements in laboratory ratios associated with responses to immunotherapy were observed in at least two participants after a single 4-hour Hemopurifier treatment[9]. - Aethlon initiated an evaluation of Hemopurifier compatibility with a simplified blood treatment system, potentially leading to easier treatments in oncology units[14]. - The company is collaborating with UCSF on Long COVID research, with a manuscript in preparation for a peer-reviewed journal[7]. Compliance and Governance - Aethlon remains in good standing with Nasdaq, resolving compliance matters[7].